Method

Oncogenicity Variant Interpreter (OncoVI)

Automated criteria-based somatic oncogenicity interpretation method.

Overview

An explanatory profile has not yet been reviewed for this record.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

Evaluations and results

4 evaluations · 25 results. Different protocols are not a single leaderboard.

Sorted by Accuracy (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.

Tested configuration	Protocol and dataset	Accuracy	Correlation (correlation type not stated)	Percent agreement (gene role: oncogene)	Percent agreement (gene role: tumour suppressor)	Percent agreement (variant type: missense)	Percent agreement (variant type: truncating)	Recall (class: oncogenic)	Accuracy (gene role: oncogene)	Accuracy (gene role: tumour suppressor)	Accuracy (variant type: missense)	Accuracy (variant type: truncating)	Percent agreement	Percent agreement (class: benign)	Percent agreement (class: VUS)	Percent agreement (oncogenic vs pathogenic)	Percent agreement (prior mtb classification vs expert reassessment)	Percent agreement (vs expert reassessment)	Recall (class: benign)
OncoVI 2026 publication configurationEvaluation	OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions, ClinVar April 2025 oncogenicity assertions	83% (best in column)	Not reported	76.1%	85.7% (best in column)	81.1% (best in column)	87.5% (best in column)	84%	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported
OncoVI 2026 publication configurationEvaluation	OncoVI three-class assessment: Guideline SOP variants, Guideline SOP variants	81%	0.87 (best in column)	Not reported	Not reported	Not reported	Not reported	88% (best in column)	82%	87.1%	83.1%	77.7%	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	83%
OncoVI 2026 publication configurationEvaluation	OncoVI three-class assessment: MTB selected expert reassessment, MTB selected expert reassessment	Not reported	0.7	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	Not reported	22%	80%	Not reported
OncoVI 2026 publication configurationEvaluation	OncoVI three-class assessment: Erlangen MTB variants, Erlangen MTB variants	Not reported	Not reported	82.5% (best in column)	76%	78.2%	49.4%	Not reported	Not reported	Not reported	Not reported	Not reported	78%	43%	97%	79%	Not reported	Not reported	Not reported

All 25 result rows with coverage, uncertainty and sources

Filter evaluations

Tested model or methodProtocolDatasetEvaluation setupMetricEvidence origin

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configuration	Protocol and dataset	Finding	Evidence and details
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	83% Accuracy percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	81.1% Percent agreement (variant type: missense) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, missense_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	76.1% Percent agreement (gene role: oncogene) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, oncogene_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	84% Recall (class: oncogenic) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, oncogenic_sensitivity; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	87.5% Percent agreement (variant type: truncating) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, truncating_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: ClinVar April 2025 oncogenicity assertions Dataset: ClinVar April 2025 oncogenicity assertions	85.7% Percent agreement (gene role: tumour suppressor) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: ClinVar April 2025 oncogenicity assertions Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, ClinVar April 2025 oncogenicity assertions, tsg_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment	80% Percent agreement (vs expert reassessment) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: MTB selected expert reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, MTB selected expert reassessment, expert_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment	22% Percent agreement (prior mtb classification vs expert reassessment) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: MTB selected expert reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, MTB selected expert reassessment, prior_mtb_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: MTB selected expert reassessment Dataset: MTB selected expert reassessment	0.7 Correlation (correlation type not stated) unitless · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: MTB selected expert reassessment Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Figure 4C, concordant variants only
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	43% Percent agreement (class: benign) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, benign_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	78% Percent agreement percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	78.2% Percent agreement (variant type: missense) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, missense_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	82.5% Percent agreement (gene role: oncogene) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogene_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	79% Percent agreement (oncogenic vs pathogenic) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogenic_vs_pathogenic_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	49.4% Percent agreement (variant type: truncating) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, truncating_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	76% Percent agreement (gene role: tumour suppressor) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, tsg_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants	97% Percent agreement (class: VUS) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Erlangen MTB variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, vus_concordance; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	81% Accuracy percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	83% Recall (class: benign) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, benign_sensitivity; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	83.1% Accuracy (variant type: missense) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, missense_accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	82% Accuracy (gene role: oncogene) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, oncogene_accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	88% Recall (class: oncogenic) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, oncogenic_sensitivity; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	0.87 Correlation (correlation type not stated) unitless · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Figure 2B, concordant variants only
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	77.7% Accuracy (variant type: truncating) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, truncating_accuracy; subgroup values correspond to Supplemental Table S6
Configuration: OncoVI 2026 publication configuration	Protocol: OncoVI three-class assessment: Guideline SOP variants Dataset: Guideline SOP variants	87.1% Accuracy (gene role: tumour suppressor) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible	Author-reported evaluation · Source checked Methods, coverage and source OncoVI: Guideline SOP variants Not reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Guideline SOP variants, tsg_accuracy; subgroup values correspond to Supplemental Table S6

Source checking is not independent reproduction. Release 2026-11-02-a7f03c9e55a5.

Use this method

How it works, versions and access

Versions and evaluated configurations

OncoVI 2026 publication configuration · configuration of

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

1 evidence row matching the loaded filters

Claims, original sources and review scope · Release 2026-11-02-a7f03c9e55a5
Property and statement	Original source and location	Review and provenance
Facets: method types 1 values conventional_pipeline Individual claims	Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology Original source ↗ OncoVI Methods: "an IF-ELSE implementation" of the points-based SOP Version: 2026 final full text in Europe PMC XML Retrieved: 2026-09-30T21:23:41Z	conflicting claim ["source-hash-verification","automated-source-review"] · 2026-10-12 Audit details Correct the method type from none to conventional_pipeline (use-case baseline review 2026-10-12, table 2). Evidence from docs/reviews/use-cases/baselines-2026-10-12.md. Independent review 2026-10-12: approved. See docs/reviews/2026-10-12-method-type-corrections.md. Conflicting source claim: `"[\"conventional_pipeline\"]"`. Claim record status: source_checked. Field: `facets.method_types` Claim: metadata-correction-tags-20261012-b9c9dcb8cfa4018bfd02 Source artifact SHA-256: `1ced323acfac29704bccfd990cc57692770c324ae598983c6973d271aaaf48b2` Hash scope: Hash scope not separately documented; inspect source record Inspected artifact Extraction artifact SHA-256: `69ac0b1ef3902b1cb6461c87117db1af4b2035e6a84ab602b0c1d02fc898d28d` Extraction artifact

How to read the evidence

Sources and history

Release 2026-11-02-a7f03c9e55a5 · Record review: source checked

1 source record and release history

Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Original source · 2026 final full text in Europe PMC XML

Download this release (gzip)

Technical metadata and extraction receipts

Stable ID: uc-clinical-20260930-method-oncovi

areas: dna-genomes
contexts: clinical_research
method types: conventional_pipeline
source locator: Methods and OncoVI implementation
review: method: automated-source-review; reviewer: codex; date: 2026-09-30; note: Transcription from inspected primary source. No execution, independent replication or human scientific review.; source id: uc-clinical-20260930-source-oncovi; reviewer note: role: clinical coverage worker

Related records

subject: Oncogenicity Variant Interpreter (OncoVI): facets.method_types
configuration of: OncoVI 2026 publication configuration

Suggest a correction